These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

3828 related items for PubMed ID: 16705046

  • 1. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL, Watson KD, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register.
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL, Symmons DP, Watson KD, Silman AJ, British Society for Rheumatology Biologics Register.
    Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520
    [Abstract] [Full Text] [Related]

  • 3. Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients.
    Valleala H, Korpela M, Möttönen T, Hienonen-Kempas T, Kauppi M, Hannonen P, Leirisalo-Repo M.
    Scand J Rheumatol; 2009 Jun; 38(5):323-7. PubMed ID: 19585384
    [Abstract] [Full Text] [Related]

  • 4. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.
    Weaver AL, Lautzenheiser RL, Schiff MH, Gibofsky A, Perruquet JL, Luetkemeyer J, Paulus HE, Xia HA, Leff JA, RADIUS Investigators.
    Curr Med Res Opin; 2006 Jan; 22(1):185-98. PubMed ID: 16393444
    [Abstract] [Full Text] [Related]

  • 5. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
    Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, Brown C, Fraser A, Jarret S, Emery P.
    Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register.
    Soliman MM, Hyrich KL, Lunt M, Watson KD, Symmons DP, Ashcroft DM, British Society for Rheumatology Biologics Register.
    J Rheumatol; 2012 Feb; 39(2):240-6. PubMed ID: 22174201
    [Abstract] [Full Text] [Related]

  • 7. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register.
    Kristensen LE, Kapetanovic MC, Gülfe A, Söderlin M, Saxne T, Geborek P.
    Rheumatology (Oxford); 2008 Apr; 47(4):495-9. PubMed ID: 18316338
    [Abstract] [Full Text] [Related]

  • 8. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
    Cañete JD, Suárez B, Hernández MV, Sanmartí R, Rego I, Celis R, Moll C, Pinto JA, Blanco FJ, Lozano F.
    Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
    [Abstract] [Full Text] [Related]

  • 9. Anti-TNF-alpha agents are less effective for the treatment of rheumatoid arthritis in current smokers.
    Abhishek A, Butt S, Gadsby K, Zhang W, Deighton CM.
    J Clin Rheumatol; 2010 Jan; 16(1):15-8. PubMed ID: 20051749
    [Abstract] [Full Text] [Related]

  • 10. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
    Wolfe F, Michaud K.
    Arthritis Rheum; 2004 Jun; 50(6):1740-51. PubMed ID: 15188349
    [Abstract] [Full Text] [Related]

  • 11. Assessment of anti-TNF-alpha efficacy in rheumatoid arthritis: is 3 months sufficient?
    Pocock JM, Vasconcelos JC, Ostör AJ.
    Rheumatology (Oxford); 2008 Jul; 47(7):1073-6. PubMed ID: 18503089
    [Abstract] [Full Text] [Related]

  • 12. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy.
    Pease C, Pope JE, Truong D, Bombardier C, Widdifield J, Thorne JC, Paul Haraoui B, Psaradellis E, Sampalis J, Bonner A.
    Semin Arthritis Rheum; 2011 Aug; 41(1):81-9. PubMed ID: 21168187
    [Abstract] [Full Text] [Related]

  • 13. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC, REFLEX Trial Group.
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [Abstract] [Full Text] [Related]

  • 14. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.
    Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Gabay C, van Riel PL, Nordström DC, Gomez-Reino J, Pavelka K, Tomsic M, Kvien TK, van Vollenhoven RF.
    Ann Rheum Dis; 2011 Sep; 70(9):1575-80. PubMed ID: 21571731
    [Abstract] [Full Text] [Related]

  • 15. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
    Quartuccio L, Fabris M, Salvin S, Atzeni F, Saracco M, Benucci M, Cimmino M, Morassi P, Masolini P, Pellerito R, Cutolo M, Puttini PS, De Vita S.
    Rheumatology (Oxford); 2009 Dec; 48(12):1557-9. PubMed ID: 19789202
    [Abstract] [Full Text] [Related]

  • 16. The prevalence of patients with rheumatoid arthritis in the West Midlands fulfilling the BSR criteria for anti-tumour necrosis factor therapy: an out-patient study.
    Yee CS, Filer A, Pace A, Douglas K, Situnayake D, Rowe IF, West Midlands Rheumatology Services and Training Committee.
    Rheumatology (Oxford); 2003 Jul; 42(7):856-9. PubMed ID: 12730544
    [Abstract] [Full Text] [Related]

  • 17. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
    Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollerup G, Linde L, Lindegaard HM, Poulsen UE, Schlemmer A, Jensen DV, Jensen S, Hostenkamp G, Østergaard M, All Departments of Rheumatology in Denmark.
    Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
    [Abstract] [Full Text] [Related]

  • 18. Rituximab therapy in patients with resistant rheumatoid arthritis: real-life experience.
    Jois RN, Masding A, Somerville M, Gaffney K, Scott DG.
    Rheumatology (Oxford); 2007 Jun; 46(6):980-2. PubMed ID: 17384180
    [Abstract] [Full Text] [Related]

  • 19. Relationship between pack-year history of smoking and response to tumor necrosis factor antagonists in patients with rheumatoid arthritis.
    Mattey DL, Brownfield A, Dawes PT.
    J Rheumatol; 2009 Jun; 36(6):1180-7. PubMed ID: 19447930
    [Abstract] [Full Text] [Related]

  • 20. Clinical significance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
    Cañete JD, Celis R, Moll C, Izquierdo E, Marsal S, Sanmartí R, Palacín A, Lora D, de la Cruz J, Pablos JL.
    Ann Rheum Dis; 2009 May; 68(5):751-6. PubMed ID: 18495732
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 192.